Portal de Periódicos da CAPES

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

2024; Springer Nature; Volume: 131; Issue: 5 Linguagem: Inglês

10.1038/s41416-024-02776-7

1532-1827

Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, Andrés Redondo, Angela George, Jane Yuet Ching Hui, Aicha Seiller, Mario Liste-Hermoso, J. Willis, Colby S. Shemesh, Jim Xiao, Kevin K. Lin, Luciana Molinero, Yinghui Guan, Isabelle Ray‐Coquard, Linda Mileshkin,

Ovarian cancer diagnosis and treatment

Abstract Background Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in advanced gynaecological or triple-negative breast cancer (TNBC). Methods After identifying the recommended dose, patients with PARPi-naive BRCA-mutated or homologous recombination-deficient/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab. Tumour biopsies were collected pre-treatment, during single-agent rucaparib run-in, and after starting combination therapy. Results The most common adverse events with rucaparib 600 mg twice daily and atezolizumab 1200 mg on Day 1 every 3 weeks were gastrointestinal effects, fatigue, liver enzyme elevations, and anaemia. Responding patients typically had BRCA-mutated tumours and higher pre-treatment tumour levels of PD-L1 and CD8 + T cells. Markers of DNA damage repair decreased during rucaparib run-in and combination treatment in responders, but typically increased in non-responders. Apoptosis signature expression showed the reverse. CD8 + T-cell activity and STING pathway activation increased during rucaparib run-in, increasing further with atezolizumab. Conclusions In this small study, rucaparib plus atezolizumab demonstrated acceptable safety and activity in BRCA-mutated tumours. Increasing anti-tumour immunity and inflammation might be a key mechanism of action for clinical benefit from the combination, potentially guiding more targeted development of such regimens. Clinical trial registration ClinicalTrials.gov (NCT03101280).